Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.45 |
| ▸ | CCR2 | P41597 | 6/20 | 0.45 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3602237 | 0.85 | SMN1; SMN2 (0.73) | KMT2ASMN1; SMN2PTGDR2TDP1GAA | |
| SCHEMBL6052538 | 0.83 | KMT2A (0.55) | KMT2ASMN1; SMN2GAANOTUMTSHR | |
| SCHEMBL21333090 | 0.82 | MITF (0.48) | KMT2ASMN1; SMN2PTGDR2TDP1HTT | |
| SCHEMBL15873981 | 0.77 | KLKB1 (0.47) | KMT2ASMN1; SMN2 | |
| SCHEMBL21523730 | 0.77 | TDP1 (0.49) | KMT2ASMN1; SMN2PTGDR2TDP1GAA | |
| SCHEMBL1198911 | 0.76 | MEN1 (0.52) | KMT2A | |
| SCHEMBL1923196 | 0.76 | HPGD (0.48) | SMN1; SMN2PTGDR2ABCB11GAAHTT | |
| SCHEMBL21523758 | 0.75 | HTT (0.50) | KMT2ASMN1; SMN2PTGDR2TDP1GAA | |
| SCHEMBL2402900 | 0.73 | NOTUM (0.57) | KMT2ATDP1HTTGFERNOTUM | |
| SCHEMBL3602948 | 0.73 | SCD5 (0.48) | KMT2APTGDR2ABCB11GAAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041696-A1 | Compounds | SMITHKLINE BEECHAM CORPORATION | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041696-A1 | Compounds | CYP11B2, SCD, CYP3A5 | KMT2A 3500/4885SMN1; SMN2 618/4885PTGDR2 911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.